MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) has received a consensus recommendation of "Buy" from the five brokerages that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $12.00.
Separately, StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th.
Get Our Latest Analysis on MiMedx Group
MiMedx Group Trading Up 2.2 %
MiMedx Group stock traded up $0.21 during midday trading on Friday, reaching $9.68. The stock had a trading volume of 548,911 shares, compared to its average volume of 1,044,440. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $9.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 17.60 and a beta of 1.98. The firm's fifty day simple moving average is $7.28 and its two-hundred day simple moving average is $6.96.
Institutional Investors Weigh In On MiMedx Group
A number of institutional investors have recently modified their holdings of MDXG. Isthmus Partners LLC raised its holdings in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock worth $27,000 after acquiring an additional 91,714 shares in the last quarter. Blue Trust Inc. acquired a new position in MiMedx Group in the 3rd quarter worth about $30,000. Point72 Asset Management L.P. purchased a new stake in shares of MiMedx Group during the 2nd quarter worth about $40,000. Point72 DIFC Ltd lifted its holdings in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after buying an additional 4,275 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in shares of MiMedx Group in the 3rd quarter valued at approximately $64,000. Institutional investors and hedge funds own 79.15% of the company's stock.
About MiMedx Group
(
Get Free ReportMiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
